BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

IN8bio (INAB)IN8bioCompany update

Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell

Related news

INABIN8bio2026-07-09 12:00 EST

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

INABIN8bio2026-08-06 20:01 EST

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

LYELLyell Immunopharma2026-06-12 16:45 EST

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

BMYBMYBristol-Myers Squibb Company2026-06-02 12:00 EST

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

NRIXNurix Therapeutics2026-06-11 11:00 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

IMTXImmatics2026-06-01 12:00 EST

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

IMTXImmatics2026-05-30 12:00 EST

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

KURAKura Oncology2026-06-11 12:02 EST

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-08-06 20:01 EST

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INABIN8bio2026-07-09 12:00 EST

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

INABIN8bio2026-06-03 12:30 EST

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

INABIN8bio2026-06-01 12:30 EST

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

INABIN8bio2026-05-14 12:00 EST

IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma

Stock data

Close
0.97 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States